Comparison of the efficacy and safety of three vasoactive agents-dopamine, norepinephrine, and epinephrine-in the treatment of patients with pulmonary hypertension crisis: prospective, randomised controlled trial monitored by haemodynamic monitoring
Age > 18 years old;
Signed informed consent form;
Confirmed diagnosis of arterial pulmonary hypertension (PAH) and/or chronic thromboembolic pulmonary hypertension (CTEPH);
Presenting with manifestations of pulmonary hypertensive crisis;
At SCAI stage D or stage E ;
Patients who only receive a diagnosis but no treatment in the hospital;
Uncontrolled hyperthyroidism;
Complicated with angle-closure glaucoma;
China National Center for Cardiovascular Diseases
Lead sponsor
Chinese Academy of Medical Sciences, Fuwai Hospital
Sponsor institution